Spring Bank to Present at Piper Jaffray's 29th Annual Healthcare Conference

HOPKINTON, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. SBPH, a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin J. Driscoll, chairman, president, and chief executive officer of Spring Bank, and Nezam H. Afdhal, MD, chief scientific officer of Spring Bank, will present at the upcoming Piper Jaffray Healthcare Conference as follows:  

Piper Jaffray 29^th Annual Healthcare Conference

Date:                           November 29, 2017

Time:                           9:50am Eastern Standard Time

Location:                     Lotte New York Palace Hotel; New York, NY

About Spring Bank

Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. The company is developing its most advanced SMNH product candidate, inarigivir soproxil (formerly referred to as SB 9200), for the treatment of viral diseases, including hepatitis B virus (HBV) and other SMNH product candidates, including SB 11285, the Company's lead immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of INterferon Genes, or STING, pathway.

Contacts

For investor inquires:

Spring Bank Pharmaceuticals, Inc.

Jonathan Freve

Chief Financial Officer

(508) 473-5993

LifeSci Advisors, LLC

Andrew McDonald

(646) 597-6987

andrew@lifesciadvisors.com

Media contact:

Josephine Belluardo, Ph.D.

LifeSci Public Relations

(646) 751-4361

jo@lifescipublicrelations.com